Move to topTop
August 06, 2018

TOKYO, JAPAN - August 6, 2018 - Terumo Corporation (TSE: 4543) today announced that WEGO Terumo (Weihai) Medical Products Co., Ltd, its affiliated company in China, received an approval to manufacture and sell peritoneal dialysis (PD) solution in July.

The affiliated company was established as a joint venture of WEGO Blood Purification Products Co., Ltd and Terumo. With the conclusion of the approval, the company will start to manufacture PD solution and related medical devices. WEGO group plans to launch those products in 2018. Terumo provides the affiliated company with technology and trademark license. Furthermore, Terumo gives marketing support to a WEGO group company which sells products and operates after-sales services.

With the strategic business alliance with WEGO group, Terumo aims for further PD dissemination in the fast growing Chinese dialysis market, by combining Terumo's technology and expertise in PD and WEGO's strong market presence with nationwide sales network.

Notes: Terumo's PD business

Terumo has been promoting the dissemination and expansion of PD since the company began the development of PD system in 1980. Terumo has been leading this field in Japan by providing innovation including Japan's first neutralized dialysate.

Notes: The Chinese dialysis market

In China, approximately 3,000,000 people are suffering from End-Stage Renal Disease (ESRD). The figure is estimated to reach approximately 4,500,000 within the next 10 years. Over 80,000 ESRD patients are currently receiving Peritoneal Dialysis (PD) therapy, forming the world largest PD market. The PD patient population is estimated to reach approximately 200,000 within the next 10 years.

*The numbers are estimated by WEGO

Notes: Terumo's regional strategy for China

Terumo has pursued its strategy in each region appropriately to the local market and its position there, while globalizing uniformly under business-led management. Terumo has moved to localize its business in China, entering into alliances with local players in selected fields, including renal denervation catheters and neuroendovascular therapy. In July 2018, Terumo entered into an agreement to acquire a specialized enterprise of drug-eluting stents in the field of coronary intervention.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.